# Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes

> **NCT00399711** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 560 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** repaglinide and metformin combination tablet
- **DRUG:** rosiglitazone and metformin combination tablet

## Key facts

- **NCT ID:** NCT00399711
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 560 (ACTUAL)
- **Last updated:** 2017-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00399711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00399711, "Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00399711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*